{"entity":{"id":"invictus","kind":"trial","name":"INVICTUS","aka":[],"tldr":"Ripretinib kept fourth-line GIST under control six times longer than placebo and improved survival.","summary":"INVICTUS, trial NCT03353753 sponsored by Deciphera and published in Lancet Oncology in 2020, showed that the switch-control kinase inhibitor ripretinib keeps fourth-line gastrointestinal stromal tumour under control roughly six times longer than placebo and improves survival. It randomised 129 patients after at least three kinase inhibitors and met its primary progression-free survival endpoint with a very large effect and a survival benefit, leading to approval in May 2020. OnCo links it to sarcomas and GIST, KIT as a target and ripretinib. Whether ripretinib can move earlier in the sequence, which INTRIGUE and the mutation-selected INSIGHT trial address, is the open question.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT03353753","url":"https://clinicaltrials.gov/study/NCT03353753"}],"tags":[],"related":[],"cancers":["sarcoma","gist-imatinib-resistant"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["kit"],"drugs":["ripretinib"],"companies":["deciphera"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03353753","phase":"3","setting":"Advanced GIST after ≥3 kinase inhibitors: ripretinib vs placebo","sponsor":"Deciphera","result":"PFS HR 0.15; OS HR 0.36.","started":"2018-02-27","startedType":"actual","yearReported":2020,"enrolled":129,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival (median)","primary":true,"unit":"months","arms":[{"name":"Ripretinib","n":85,"value":6.3},{"name":"Placebo","n":44,"value":1}],"hr":0.15,"ci":[0.09,0.25],"p":"<0.0001","source":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30168-6/fulltext"},{"endpoint":"Overall survival (median)","unit":"months","arms":[{"name":"Ripretinib","value":15.1},{"name":"Placebo","value":6.6}],"hr":0.36,"source":"https://doi.org/10.1016/S1470-2045(20)30168-6"}]},"route":"/trials/invictus/","neighbours":{"cancer":[{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"}],"drug":[{"id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/"}],"company":[{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/"}],"paper":[{"id":"paper-invictus-ripretinib-lancet-oncol-2020","kind":"paper","name":"INVICTUS: ripretinib in advanced gastrointestinal stromal tumours after three or more prior kinase inhibitors","route":"/key-papers/paper-invictus-ripretinib-lancet-oncol-2020/"}]}}